Journal of Nuclear Medicine最新文献

{"title":"The Future of Nuclear Medicine in the United States.","authors":"George M Segall, Maria Watts, Kirk A Frey","doi":"10.2967/jnumed.123.265674","DOIUrl":"10.2967/jnumed.123.265674","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monte Carlo Simulations Corroborate PET-Measured Discrepancies in Activity Assessments of Commercial ⁹⁰Y Vials.","authors":"Lucrezia Auditore,&nbsp;Daniele Pistone,&nbsp;Antonio Italiano,&nbsp;Ernesto Amato,&nbsp;Silvano Gnesin","doi":"10.2967/jnumed.123.265494","DOIUrl":"https://doi.org/10.2967/jnumed.123.265494","url":null,"abstract":"<p><p>In a recent multicenter study, discrepancies between PET/CT-measured activity and vendor-calibrated activity for ⁹⁰Y glass and resin microspheres were found. In the present work, the origin of these discrepancies was investigated by Monte Carlo (MC) simulations. <b>Methods:</b> Three vial configurations, containing ⁹⁰Y-chloride, ⁹⁰Y-labeled glass microspheres, and ⁹⁰Y-labeled resin microspheres, were modeled with GAMOS, and the electric signal generated in an activity meter was simulated. Energy deposition was scored in the activity meter-active regions and converted into electric current per unit activity. Internal bremsstrahlung (IB) photons, always accompanying β-decay, were simulated in addition to ⁹⁰Y decays. The electric current per source activity obtained for ⁹⁰Y glass and resin microspheres, I_glass and I_resin, was compared in terms of relative percentage difference with that of ⁹⁰Y-chloride ([Formula: see text] and [Formula: see text]) and each other (δ). The findings of this work were compared with the ones obtained through PET measurements in the multicenter study. <b>Results:</b> With the inclusion of IB photons as primary particles in MC simulations, the [Formula: see text] and [Formula: see text] results were 24.6% ± 3.9% and -15.0% ± 2.2%, respectively, whereas δ was 46.5% ± 1.9%, in very good agreement with the values reported in the multicenter study. <b>Conclusion:</b> The MC simulations performed in this study indicate that the discrepancies recently found between PET/CT-measured activity and vendor-calibrated activity for ⁹⁰Y glass and resin microspheres can be attributed to differences in the geometry of the respective commercial vials and to the metrologic approach adopted for activity meter calibration with a ⁹⁰Y-chloride liquid source. Furthermore, IB photons were shown to play a relevant role in determining the electric current in the activity meter.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10538250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10194146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Future of Nuclear Medicine in the United States.","authors":"Michael M Graham","doi":"10.2967/jnumed.122.265314","DOIUrl":"10.2967/jnumed.122.265314","url":null,"abstract":"<p><p>Nuclear medicine (NM) in the United States is experiencing a manpower shortage that is steadily getting worse. It largely derives from inadequate production of well-trained NM physicians. It is different in the rest of the world, where NM is an independent specialty and training is more rigorous. Three suggestions are offered to help reverse the situation: (1) stop radiologists with inadequate training from practicing NM; (2) strengthen NM training programs; and (3) inform medical students of career opportunities in NM. If we do nothing, the rest of the world will move forward, leaving us behind.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10294777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-Time-Point Posttherapy ¹⁷⁷Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome.","authors":"Manuela Straub,&nbsp;Jürgen Kupferschläger,&nbsp;Lina Maria Serna Higuita,&nbsp;Matthias Weissinger,&nbsp;Helmut Dittmann,&nbsp;Christian la Fougère,&nbsp;Francesco Fiz","doi":"10.2967/jnumed.122.264770","DOIUrl":"https://doi.org/10.2967/jnumed.122.264770","url":null,"abstract":"<p><p>¹⁷⁷Lu-PSMA-617 is an effective therapeutic option in metastasized castration-resistant prostate cancer (mCRPC). However, some patients progress under treatment. We hypothesized that the tracer kinetics within the metastases may influence the therapy effectiveness and tested this hypothesis by analyzing uptake parameters on 2 consecutive posttherapy SPECT/CT scans. <b>Methods:</b> mCRPC patients treated with ¹⁷⁷Lu-PSMA-617 and with available posttherapy SPECT/CT imaging (24 and 48 h after the first treatment) were enrolled retrospectively. Volumes of interest were defined on lymph node metastasis (LNM) and bone metastasis (BM) on both SPECT/CT scans. The reduction of the percentage injected dose (%IDred) between the 2 SPECT/CT scans was computed. We compared %IDred of responders (prostate-specific antigen drop ≥ 50% after 2 cycles of ¹⁷⁷Lu-PSMA-617) and nonresponders. We tested the association of %IDred with progression-free survival and overall survival (OS) using a univariate Kaplan-Meier (KM) analysis and a multivariate Cox regression model. <b>Results:</b> Fifty-five patients (median age, 73 y; range, 54-87 y) were included. %IDred in LNM and BM was greater in nonresponders than in responders (for LNM, 36% in nonresponders [interquartile range (IQR), 26%-47%] vs. 24% in responders [IQR, 12%-33%] [<i>P</i> = 0.003]; for BM, 35% in nonresponders [IQR, 27%-52%] vs. 18% in responders [IQR, 15%-29%] [<i>P</i> = 0.002]). For progression-free survival, in KM analysis, greater %IDred in LNM (<i>P</i> = 0.008) and BM (<i>P</i> = 0.001) was associated with shorter survival, whereas in multivariate analysis, only %IDred in LNM was retained (<i>P</i> = 0.03). In univariate KM analysis of OS, greater %IDred in BM was associated with shorter survival (<i>P</i> = 0.002). In multivariate OS analysis, BM %IDred (<i>P</i> = 0.009) was retained. <b>Conclusion:</b> The ¹⁷⁷Lu-PSMA-617 clearance rate from mCRPC metastases appears to be a relevant prognosticator of response and survival, with faster clearing possibly signaling a shorter radiopharmaceutical residence time and absorbed dose. Dual-time-point analysis appears to be a feasible and readily available approach to estimate the likelihood of response and patients' survival.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10165782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-PSMA-617 Radionuclide Therapy.","authors":"Thomas A Hope,&nbsp;Emmanuel S Antonarakis,&nbsp;Lisa Bodei,&nbsp;Jeremie Calais,&nbsp;Amir Iravani,&nbsp;Heather Jacene,&nbsp;Phillip J Koo,&nbsp;Alicia K Morgans,&nbsp;Joseph R Osborne,&nbsp;Scott T Tagawa,&nbsp;Mary-Ellen Taplin,&nbsp;Oliver Sartor,&nbsp;Michael J Morris","doi":"10.2967/jnumed.123.265952","DOIUrl":"https://doi.org/10.2967/jnumed.123.265952","url":null,"abstract":"Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota; Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; Department of Radiology, University of Washington, Seattle, Washington; Department of Radiology, Brigham and Women’s Hospital, and Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts; Banner M.D. Anderson Cancer Center, Phoenix, Arizona; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York; Mayo Clinic, Rochester, Minnesota; and Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10221822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Epidermal Growth Factor Receptor 2-Targeting [⁶⁸Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer.","authors":"Ali Alhuseinalkhudhur,&nbsp;Henrik Lindman,&nbsp;Per Liss,&nbsp;Tora Sundin,&nbsp;Fredrik Y Frejd,&nbsp;Johan Hartman,&nbsp;Victor Iyer,&nbsp;Joachim Feldwisch,&nbsp;Mark Lubberink,&nbsp;Caroline Rönnlund,&nbsp;Vladimir Tolmachev,&nbsp;Irina Velikyan,&nbsp;Jens Sörensen","doi":"10.2967/jnumed.122.265364","DOIUrl":"https://doi.org/10.2967/jnumed.122.265364","url":null,"abstract":"<p><p>Imaging using the human epidermal growth factor receptor 2 (HER2)-binding tracer ⁶⁸Ga-labeled Z_HER2:2891-Cys-MMA-DOTA ([⁶⁸Ga]Ga-ABY-025) was shown to reflect HER2 status determined by immunohistochemistry and in situ hybridization in metastatic breast cancer (MBC). This single-center open-label phase II study investigated how [⁶⁸Ga]Ga-ABY-025 uptake corresponds to biopsy results and early treatment response in both primary breast cancer (PBC) planned for neoadjuvant chemotherapy and MBC. <b>Methods:</b> Forty patients with known positive HER2 status were included: 19 with PBC and 21 with MBC (median, 3 previous treatments). [⁶⁸Ga]Ga-ABY-025 PET/CT, [¹⁸F]F-FDG PET/CT, and core-needle biopsies from targeted lesions were performed at baseline. [¹⁸F]F-FDG PET/CT was repeated after 2 cycles of therapy to calculate the directional change in tumor lesion glycolysis (Δ-TLG). The largest lesions (up to 5) were evaluated in all 3 scans per patient. SUVs from [⁶⁸Ga]Ga-ABY-025 PET/CT were compared with the biopsied HER2 status and Δ-TLG by receiver operating characteristic analyses. <b>Results:</b> Trial biopsies were HER2-positive in 31 patients, HER2-negative in 6 patients, and borderline HER2-positive in 3 patients. The [⁶⁸Ga]Ga-ABY-025 PET/CT cutoff SUV_max of 6.0 predicted a Δ-TLG lower than -25% with 86% sensitivity and 67% specificity in soft-tissue lesions (area under the curve, 0.74 [95% CI, 0.67-0.82]; <i>P</i> = 0.01). Compared with the HER2 status, this cutoff resulted in clinically relevant discordant findings in 12 of 40 patients. Metabolic response (Δ-TLG) was more pronounced in PBC (-71% [95% CI, -58% to -83%]; <i>P</i> < 0.0001) than in MBC (-27% [95% CI, -16% to -38%]; <i>P</i> < 0.0001), but [⁶⁸Ga]Ga-ABY-025 SUV_max was similar in both with a mean SUV_max of 9.8 (95% CI, 6.3-13.3) and 13.9 (95% CI, 10.5-17.2), respectively (<i>P</i> = 0.10). In multivariate analysis, global Δ-TLG was positively associated with the number of previous treatments (<i>P</i> = 0.0004) and negatively associated with [⁶⁸Ga]Ga-ABY-025 PET/CT SUV_max (<i>P</i> = 0.018) but not with HER2 status (<i>P</i> = 0.09). <b>Conclusion:</b> [⁶⁸Ga]Ga-ABY-025 PET/CT predicted early metabolic response to HER2-targeted therapy in HER2-positive breast cancer. Metabolic response was attenuated in recurrent disease. [⁶⁸Ga]Ga-ABY-025 PET/CT appears to provide an estimate of the HER2 expression required to induce tumor metabolic remission by targeted therapies and might be useful as an adjunct diagnostic tool.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10538247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of ⁶⁸Ga-FAPI PET/CT and ¹⁸F-FDG PET/CT.","authors":"Xuetao Chen, Shuailiang Wang, Yumei Lai, Guochang Wang, Maomao Wei, Xiao Jin, Jin Ding, Yan Zhang, Yunfei Shi, Feng Wang, Hua Zhu, Zhi Yang, Xuejuan Wang","doi":"10.2967/jnumed.123.265530","DOIUrl":"10.2967/jnumed.123.265530","url":null,"abstract":"<p><p>Our objective was to compare the diagnostic performance of ⁶⁸Ga-labeled fibroblast activation protein (FAP) inhibitor (FAPI) and ¹⁸F-labeled FDG PET/CT in diagnosing lymphomas and to characterize the influence of FAP and glycolytic markers on tracer uptake by involved lesions. <b>Methods:</b> Participants with different lymphoma subtypes who were prospectively recruited from May 2020 to December 2021 underwent ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT. Immunohistochemistry was performed to evaluate FAP, hexokinase 2, and glucose transporter 1 (GLUT1) expression, and the paired-samples <i>t</i> test and Wilcoxon signed-rank test were used to compare parameters. The correlation between the immunochemistry results and tracer uptake was determined by the Spearman rank correlation coefficient. <b>Results:</b> In total, 186 participants (median age, 52 y [interquartile range, 41-64 y]; 95 women) were included. Dual-tracer imaging produced 3 types of imaging profiles. ¹⁸F-FDG PET possessed a higher staging accuracy (98.4%) than ⁶⁸Ga-FAPI PET (86.0%). In 5,980 lymphoma lesions, ¹⁸F-FDG PET/CT detected more nodal (4,624 vs. 2,196) and extranodal (1,304 vs. 845) lesions than ⁶⁸Ga-FAPI PET/CT. Additionally, 52 ⁶⁸Ga-FAPI-positive/¹⁸F-FDG-negative lesions and 2,939 ⁶⁸Ga-FAPI-negative/¹⁸F-FDG-positive lesions were observed. In many lymphoma subtypes, semiquantitative evaluation revealed no significant differences in SUV_max or target-to-liver ratios between ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT (<i>P</i> > 0.05). Interestingly, GLUT1 and hexokinase 2 were overexpressed both in lymphoma cells and in the tumor microenvironment, whereas FAP was expressed only in stromal cells. FAP and GLUT1 expression correlated positively with ⁶⁸Ga-FAPI SUV_max (<i>r</i> = 0.622, <i>P</i> = 0.001) and ¹⁸F-FDG SUV_max (<i>r</i> = 0.835, <i>P</i> < 0.001), respectively. <b>Conclusion:</b> ⁶⁸Ga-FAPI PET/CT was inferior to ¹⁸F-FDG PET/CT in diagnosing lymphomas with low FAP expression. However, the former may supplement the latter and help reveal the molecular profile of lymphomas.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10537778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.","authors":"Ingo Hartlapp,&nbsp;Philipp E Hartrampf,&nbsp;Sebastian E Serfling,&nbsp;Vanessa Wild,&nbsp;Alexander Weich,&nbsp;Leo Rasche,&nbsp;Sabine Roth,&nbsp;Andreas Rosenwald,&nbsp;Patrick W Mihatsch,&nbsp;Anne Hendricks,&nbsp;Armin Wiegering,&nbsp;Verena Wiegering,&nbsp;Heribert Hänscheid,&nbsp;Andreas Schirbel,&nbsp;Rudolf A Werner,&nbsp;Andreas K Buck,&nbsp;Hans-Jürgen Wester,&nbsp;Hermann Einsele,&nbsp;Volker Kunzmann,&nbsp;Constantin Lapa,&nbsp;K Martin Kortüm","doi":"10.2967/jnumed.123.265464","DOIUrl":"https://doi.org/10.2967/jnumed.123.265464","url":null,"abstract":"<p><p>Desmoplastic small round cell tumor (DSRCT) is a rare, radiosensitive, yet difficult-to-treat sarcoma subtype affecting predominantly male adolescents. Extensive intraperitoneal seeding is common and requires multimodal management. With no standard therapy established, the prognosis remains poor, and new treatment options are needed. We demonstrate the clinical potential of C-X-C motif chemokine receptor 4 (CXCR4)-directed imaging and endoradiotherapy in DSRCT. <b>Methods:</b> Eight male patients underwent dual-tracer imaging with [¹⁸F]FDG and CXCR4-directed [⁶⁸Ga]pentixafor PET/CT. A visual comparison of both tracers, along with uptake quantification in active DSRCT lesions, was performed. [⁶⁸Ga]pentixafor uptake was correlated with immunohistochemical CXCR4 expression on tumor cells. Four patients with end-stage progressive disease underwent CXCR4-based endoradiotherapy. We report the safety, response by RECIST 1.1, and survival after endoradiotherapy. <b>Results:</b> Uptake of [⁶⁸Ga]pentixafor in tumor lesions was demonstrated in all patients with DSRCT, providing diagnostic power comparable to [¹⁸F]FDG PET. Corresponding CXCR4 expression was confirmed by immunohistochemistry in all DSRCT biopsies. Finally, 4 patients were treated with CXCR4-directed [⁹⁰Y]endoradiotherapy, 3 in a myeloablative dose range with subsequent autologous stem cell transplantation. All 3 required transfusions, and febrile neutropenia occurred in 2 patients (resulting in 1 death). Notably, severe nonhematologic adverse events were absent. We observed signs of response in all 3 patients, translating into disease stabilization in 2 patients for 143 and 176 d, respectively. In the third patient, postmortem autopsy confirmed a partial pathologic response. <b>Conclusion:</b> We validated CXCR4 as a diagnostic biomarker and a promising target for endoradiotherapy in DSRCT, demonstrated its feasibility, and provided the first evidence of its clinical efficacy.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10519842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[¹⁸F]FDG PET/CT in the Initial Staging and Restaging of Soft-Tissue or Bone Sarcoma in Patients with Negative or Equivocal Findings for Metastases or Limited Recurrence on Conventional Work-up: Results of a Prospective Multicenter Registry.","authors":"Ur Metser, Roshini Kulanthaivelu, Abdulazeez Salawu, Albiruni Razak, Victor Mak, Xuan Li, Deanna L Langer, Pamela MacCrostie, Amit Singnurkar","doi":"10.2967/jnumed.122.265278","DOIUrl":"10.2967/jnumed.122.265278","url":null,"abstract":"<p><p>The purpose of this study was to determine the impact of [¹⁸F]FDG PET/CT on the initial staging, restaging, clinical management, and outcomes of patients with soft-tissue and bone sarcomas. <b>Methods:</b> This single-arm, prospective multicenter registry enrolled 304 patients with 320 [¹⁸F]FDG PET/CT scans (November 2018 to October 2021). Eligibility included the initial staging of a grade 2 or higher or ungradable soft-tissue or bone sarcoma, with negative or equivocal findings for nodal or distant metastases on conventional imaging before curative-intent therapy, or restaging of patients with a history of treated sarcoma with a suspicion or confirmation of local recurrence or limited metastatic disease who were being considered for curative-intent or salvage therapy. The presence of local recurrence or metastases on [¹⁸F]FDG PET/CT was recorded. Clinical management after [¹⁸F]FDG PET/CT compared with pre-[¹⁸F]FDG PET/CT planned management and quantitative metabolic tumor parameters (SUV_max, metabolic tumor volume, total lesion glycolysis) were correlated with the outcome data for 171 patients. <b>Results:</b> At the initial staging, [¹⁸F]FDG PET/CT detected metastases in 17 of 105 patients (16.2%) with no metastases on conventional work-up and confirmed metastases in 44 of 92 patients (47.8%) with equivocal findings for metastases. At the time of restaging, [¹⁸F]FDG PET/CT detected local recurrence in 37 of 123 patients (30.1%) and distant metastases in 71 of 123 patients (57.7%). Overall, the change in treatment intent and treatment type was recorded in 64 of 171 cases (37.4%) and 56 of 171 cases (32.8%), respectively. The presence of metastases on [¹⁸F]FDG PET/CT was associated with shorter progression-free survival at the initial staging (<i>P</i> = 0.04) and shorter overall survival at the time of recurrence (<i>P</i> = 0.002). All quantitative metabolic tumor parameters correlated with progression-free survival and overall survival. <b>Conclusion:</b> [¹⁸F]FDG PET/CT frequently detects additional sites of disease compared with conventional imaging in patients with sarcomas that were being considered for curative-intent or salvage therapy. This increased detection impacts the clinical management in a third of patients referred for initial staging or presumed limited recurrence after primary therapy. The presence of metastases on [¹⁸F]FDG PET/CT is associated with poorer outcomes.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10165783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}